ArticleScientific reports2026
γ-terpinene inhibits the progression of hepatocellular carcinoma by regulating the PTEN/PI3K/Akt signaling pathway mediated glycolysis.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma (HCC) is a lethal malignancy. This study was designed to investigate the anti-HCC effects of the natural monoterpene compound γ-terpinene (γ-TPN) and its potential mechanism regulating the PTEN/PI3K/Akt pathway and glycolysis. The effects of γ-TPN on cell proliferation, migration, and invasion were assessed in vitro using EdU, colony formation, and Transwell assays. Western blotting and biochemical assay kits were employed to detect PTEN/PI3K/Akt pathway proteins and glycolytic indicators. Rescue experiments with the PTEN inhibitor bpV verified PTEN’s essential role. Finally, a subcutaneous xenograft tumor model in nude mice was established to confirm γ-TPN’s antitumor efficacy and underlying mechanism in vivo. In vitro experiments demonstrated that γ-TPN dose-dependently inhibited HCC cell proliferation, migration, and invasion. Mechanistically, γ-TPN suppressed the PI3K/Akt pathway by upregulating PTEN, which subsequently downregulated key glycolytic proteins and reduced glucose consumption, ATP production, and lactate generation. These effects were reversed by the PTEN inhibitor bpV. In vivo studies confirmed that γ-TPN markedly inhibited tumor growth and Ki67 expression, consistently suppressing the PTEN/PI3K/Akt pathway and glycolysis in tumor tissues. Collectively, γ-TPN inhibits HCC progression through PTEN upregulation, which suppresses the PI3K/Akt pathway and its associated glycolytic metabolism.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.